| 15 | 0 | 18 |
| 下载次数 | 被引频次 | 阅读次数 |
目的 探讨自拟利咽汤颗粒联合重组人干扰素α1b治疗疱疹性咽峡炎（HA）风热证患儿的临床效果。方法 收集2023年1月—2025年6月收治的HA患儿171例的临床资料，按照治疗方案不同分为对照组、干扰素组、利咽汤组，各57例。对照组接受基础治疗，干扰素组接受基础治疗+重组人干扰素α1b，利咽汤组接受基础治疗+重组人干扰素α1b+自拟利咽汤颗粒。比较3组治疗效果、中医证候积分、临床症状改善时间、炎症因子[C反应蛋白（CRP）、白细胞介素-6(IL-6)、IL-8、肿瘤坏死因子-α(TNF-α)]、免疫指标（T淋巴细胞亚群：CD3+、CD4+、CD8+、CD4+/CD8+）及不良反应。结果 利咽汤组总有效率[96.49%(55/57)]高于干扰素组[80.70%(46/57)](P<0.05)，干扰素组、对照组总有效率[70.18%(40/57)]比较差异无统计学意义（P>0.05）。利咽汤组发热、咽部疱疹、咽痛、流涎、口渴欲饮、小便黄赤和（或）大便干结积分低于干扰素组和对照组，干扰素组低于对照组（P<0.05）。治疗5 d后，利咽汤组发热消失、咽痛消失、疱疹溃疡愈合时间短于干扰素组和对照组，干扰素组短于对照组（P<0.05）。治疗5 d后，利咽汤组CRP、IL-6、IL-8、TNF-α、CD8+水平低于干扰素组和对照组，CD3+、CD4+、CD4+/CD8+水平高于干扰素组和对照组（P<0.05）；治疗5 d后，干扰素组CRP、IL-6、IL-8、TNF-α、CD8+水平低于对照组，CD3+、CD4+、CD4+/CD8+水平高于对照组（P<0.05）。3组不良反应发生率比较差异无统计学意义（P>0.05）。结论 自拟利咽汤颗粒联合重组人干扰素α1b治疗HA安全有效，可改善临床症状，加速病情缓解，抑制炎症反应，提升免疫功能。
Abstract：Objective To investigate the clinical efficacy of self-formulated Liyan Tang granules combined with recombinant human interferon α1b(rhIFN-α1b) in the treatment of children with herpangina(HA) and wind-heat syndrome. Methods The clinical data of 171 children with HA treated from January 2023 to June 2025 were collected. According to different treatment regimens, the patients were divided into a control group, an interferon group and a Liyan Tang group, with 57 patients in each group. The control group received basic treatment, the interferon group received basic treatment + rhIFN-α1b, and the Liyan Tang group received basic treatment + recombinant human interferon α1b + self-formulated Liyan Tang granules. The therapeutic efficacy, traditional Chinese medicine(TCM) syndrome score, improvement time of clinical symptoms, inflammatory factors [C-reactive protein(CRP), interleukin(IL)-6, IL-8, tumor necrosis factor-α( TNF-α)], immune indexes(T lymphocyte subsets: CD3+, CD4+, CD8+, CD4+/CD8+) and adverse reactions were compared among the three groups. Results The total effective rate of the Liyan Tang group[96.49%(55/57)] was higher than that of the interferon group [80.70%(46/57)](P<0.05), while no significant difference was found between the interferon group and the control group [70.18%(40/57)](P>0.05). The scores of fever, pharyngeal herpes, sore throat, salivation, thirst with desire to drink, yellowish red urine and/or dry stool in the Liyan Tang group were lower than those in the interferon group and the control group, and the scores in the interferon group were lower than those in the control group(P<0.05). At 5 d after treatment, the disappearance time of fever and sore throat, and the healing time of herpes and ulcer in the Liyan Tang group were shorter than those in the interferon group and the control group, and the above indexes in the interferon group were shorter than those in the control group(P<0.05). At 5 d after treatment, the levels of CRP, IL-6, IL-8, TNF-α, and CD8+ in the Liyan Tang group were lower, while the levels of CD3+, CD4+ and CD4+/CD8+ were higher than those in the interferon group and the control group(P<0.05). The interferon group had lower levels of CRP, IL-6, IL-8, TNF-α and CD8+, and higher levels of CD3+, CD4+ and CD4+/CD8+ than the control group(P<0.05). There was no significant difference in the incidence of adverse reactions among the three groups(P>0.05) Conclusion Self-formulated Liyan Tang granules combined with rhIFN-α1b is safe and effective in the treatment of HA. It can ameliorate clinical symptoms, accelerate disease remission, inhibit inflammatory response and improve immune function.
[1]Zhang W X,Zou L,Cui Y,et al. Molecular epidemiology of herpangina in the subcenter of Beijing,China:a surveillance study during 2021-2022[J]. Arch Virol,2024,169(12):245. DOI:10.1007/s00705-024-06171-8.
[2]Li R,Lin C,Dong S,et al. Phylogenetics and phylogeographic characteristics of coxsackievirus A16 in hand foot and mouth disease and herpangina cases collected in Beijing,China from 2019 to 2021[J]. J Med Virol,2023,95(8):e28991. DOI:10.1002/jmv.28991.
[3]梅昕，彭小丹，周育宏.药学门诊对儿童疱疹性咽峡炎用药干预分析[J].中国药物应用与监测，2024,21(2):192-195. DOI:10.3969/j.issn.1672-8157.2024.02.024.
[4]罗雪敏，黄东辉，邹晓惠.馥感啉口服液联合重组人干扰素α1b治疗疱疹性咽峡炎的疗效及对患儿心肌酶谱和炎症因子的影响[J].海南医学，2022,33(10):1290-1293. DOI:10.3969/j.issn.1003-6350.2022.10.018.
[5]刘连凤，史军然，薛红霞，等.重组人干扰素α1b雾化吸入治疗儿童上呼吸道病毒感染及预防儿童上呼吸道病毒感染诱发毛细支气管炎效果研究[J].临床误诊误治，2019,32(5):24-29. DOI:10.3969/j.issn.1002-3429.2019.05.006.
[6]曾盈盈.百蕊颗粒联合干扰素雾化吸入治疗儿童疱疹性咽峡炎临床观察[J].西部中医药，2021,34(11):113-115. DOI:10.12174/j.issn.2096-9600.2021.11.25.
[7]胡坤敏，程芳，朱珊.疱疹性咽峡炎从湿热论治的临床研究进展[J].临床与病理杂志，2023,43(5):1051-1056. DOI:10.11817/j.issn.2095-6959.2023.222228.
[8]唐坤泉，李妙媛，郭钦源.自拟利咽汤颗粒用于儿童C反应蛋白水平升高的疱疹性咽峡炎的疗效观察[J].贵州医药，2024,48(8):1192-1194.
[9]中华医学会儿科学分会感染学组，国家感染性疾病医疗质量控制中心，俞蕙.疱疹性咽峡炎诊断及治疗专家共识(2019年版)[J].中华儿科杂志，2019,57(3):177-180. DOI:10.3760/cma.j.issn.0578-1310.2019.03.004.
[10]汪受传.中医儿科学[M].北京：中国中医药出版社，2012:89.
[11]邓玲.中医病证诊断疗效标准[M].中国中医药出版社，2017:556-558.
[12]Wang Y,Gao F,Liang Z,et al. Establishment of the 1st Chinese national standard for CA6 neutralizing antibody[J].H u m Va c c i n I m m u n o t h e r ,2 0 2 3 ,1 9(1):2 1 6 4 1 4 0. D O I:10.1080/21645515.2022.2164140.
[13]Yamamoto-Kataoka S,Kataoka Y,Tochitani K,et al. Influence of anti-coronavirus disease 2019 policies on 10 pediatric infectious diseases[J]. Pediatr Int,2022,64(1):e14958. DOI:10.1111/ped.14958.
[14]车向郁，郝彩虹，王鸣飞，等.重组人干扰素α1b雾化吸入治疗小儿毛细支气管炎对肺功能及干扰素-γ、白细胞介素-10水平的影响[J].儿科药学杂志，2021,27(3):31-33. DOI:10.13407/j.cnki.jpp.1672-108X.2021.03.009.
[15]吴守业，林道炯，李文琳.祛风散热法联合常规治疗对急性期疱疹性咽峡炎患者的临床疗效[J].中成药，2020,42(6):1490-1493.DOI:10.3969/j.issn.1001-1528.2020.06.018.
[16]黎鸣桃，黄淑芹，张可妃，等.小儿豉翘清热颗粒联合人干扰素α2b喷雾剂对疱疹性咽峡炎患儿的疗效[J].西北药学杂志，2023,38(3):176-179. DOI:10.3969/j.issn.1004-2407.2023.03.032.
[17]唐坤泉，李妙媛.自拟利咽汤颗粒联合穴位外敷治疗小儿疱疹性咽峡炎的临床观察研究[J].系统医学，2025,10(1):4-7. DOI:10.19368/j.cnki.2096-1782.2025.01.004.
[18]刘嘉，严宝飞，曾明月，等.黄芩-金银花药对治疗新型冠状病毒肺炎潜在作用机制的网络药理学研究[J].世界中医药，2020,15(4):502-511. DOI:10.3969/j.issn.1673-7202.2020.04.006.
[19]马雪百合，郭健敏，温玉莹，等.连翘化学成分、药理作用及安全性评价的研究进展[J].中药新药与临床药理，2024,35(7):1093-1100. DOI:10.19378/j.issn.1003-9783.2024.07.018.
[20]黄玉龙，郑肇良，周燕.甘草桔梗射干汤加味治疗急性单纯性咽炎(肺胃实热证)临床研究[J].中国中医急症，2021,30(2):257-260. DOI:10.3969/j.issn.1004-745X.2021.02.019.
[21]张孝宇，孟凡娟，韩辉，等.射干的化学成分、生物活性及分子研究进展[J].中华中医药学刊，2023,41(9):179-183. DOI:10.13193/j.issn.1673-7717.2023.09.038.
[22]颜靖棠，陈蓓蕾.小儿牛黄清心散联合人干扰素喷剂α-2b治疗肠道病毒通用型引起的疱疹性咽峡炎的效果分析[J].贵州医药，2023,47(10):1543-1544.
[23]Lv T,Li Y,You P,et al. Genome analysis of coxsackievirus A4identified from herpangina children in northern China[J]. Curr Microbiol,2025,82(2):83. DOI:10.1007/s00284-025-04075-7.
[24]荣智燕，马娟珍，孙丽.孟鲁司特钠联合雾化重组人干扰素α1b对呼吸道合胞病毒肺炎的疗效[J].中华医院感染学杂志，2024,34(23):3542-3547. DOI:10.11816/cn.ni.2024-240160.
[25]凌鑫萍，晏伟，杨芬，等.绿原酸改善炎症性疾病的研究进展[J].中南大学学报（医学版），2023,48(10):1611-1620. DOI:10.11817/j.issn.1672-7347.2023.230146.
[26]杨本军，武明飞，徐涛.连翘苷调控炎症的抑制作用及机制研究[J].安徽医科大学学报，2020,55(7):1093-1097. DOI:10.19405/j.cnki.issn1000-1492.2020.07.021.
[27]张亚青，张晓伟，苏小霞，等.清热利咽汤联合喜炎平注射液治疗疱疹性咽峡炎患儿的疗效及对炎性因子和免疫功能的影响[J].现代生物医学进展，2023,23(19):3797-3800. DOI:10.13241/j.cnki.pmb.2023.19.040.
[28]陆杰，魏翠琴，李文升，等. rIFNα-2b雾化吸入联合匹多莫德对疱疹性咽峡炎患儿的影响[J].医学动物防制，2023,39(10):976-980.DOI:10.7629/yxdwfz202310013.
[29]翁艳，魏亚新.小儿金翘颗粒联合干扰素α-2b治疗小儿急性期疱疹性咽峡炎的效果及对患儿免疫功能和炎性因子的影响[J].中国妇幼保健，2023,38(19):3707-3710. DOI:10.19829/j.zgfybj.issn.1001-4411.2023.19.024.
[30]Shi D,Chen K,Lu X,et al. Recombinant human interferon-α1b inhibits SARS-CoV-2 better than interferon-α2b in vitro[J]. Virol Sin,2022,37(2):295-298. DOI:10.1016/j.virs.2022.01.031.
[31]Sun L,Bi J,Zhen W,et al. Effects of ganciclovir combined with recombinant human interferon-α on clinical efficacy and immune function in children with infectious mononucleosis[J]. Pak J Med Sci,2024,40(7):1473-1478. DOI:10.12669/pjms.40.7.8705.
[32]Chen L,Wu Y,Sun Y,et al. Combined therapy of local recombinant human interferon α1b injection and acupuncture on verruca vulgaris:a retrospective study[J]. Arch Dermatol Res,2023,315(8):2365-2373. DOI:10.1007/s00403-023-02627-0.
[33]刘斐，姚杰，张丽骞.金银花提取物联合奥曲肽对胰腺炎大鼠腺泡细胞损伤修复、免疫学指标及p38MAPK/ATF2水平的影响[J].解剖学杂志，2023,46(6):497-501. DOI:10.3969/j.issn.1001-1633.2023.06.006.
[34]刘晴晴，康锦花，龙文杰，等.基于网络药理学探讨“金银花-连翘”药对防治新型冠状病毒肺炎的作用机制[J].西部中医药，2023,36(6):19-25. DOI:10.12174/j.issn.2096-9600.2023.06.05.
[35]雷俊.牛蒡子苷元抑制TLR4/TRAF6/NF-κB信号通路对哮喘模型大鼠气道重塑和Th1/Th2免疫平衡的影响[J].免疫学杂志，2023,39(1):12-20. DOI:10.13431/j.cnki.immunol.j.20230002.
[36]李超，张欢，汲晨锋.桔梗化学成分、药理作用及现代应用研究进展[J].中国药学杂志，2025,60(1):9-20. DOI:10.11669/cpj.2025.01.002.
基本信息:
中图分类号:R766.12
引用信息:
[1]范涛,杨金凯.自拟利咽汤颗粒联合重组人干扰素α1b治疗疱疹性咽峡炎风热证患儿的临床效果[J].临床误诊误治,2026,39(10):87-92+105.
基金信息:
四川省中医药管理局科学技术研究专项项目（25MSZX257）; 攀枝花市医学研究中心医学科研项目（PYYZ-2024-16）
2026-05-28
2026-05-28